Himax, Walmart and Corcept Face Valuation Scrutiny on Elevated Forward P/E Ratios

StockStory said on May 13, 2026, that Himax Technologies (HIMX), Walmart (WMT) and Corcept Therapeutics (CORT) carry heightened downside risk because their share prices imply elevated earnings multiples. Himax, a Taiwan-based maker of display driver chips, was cited at $18.41 a share, or 29.7 times forward earnings. Walmart was listed at $130.43 a share and 44.8 times forward earnings, while Corcept Therapeutics was cited at $51.50 a share and 79.4 times forward earnings. The report argued that expensive stocks can be more volatile during market downturns when investor expectations reset. It framed the three companies as examples where valuation may not be justified by business quality or growth prospects.